Duopharma Biotech Bhd (KLSE:7148) — Stock Price
Duopharma Biotech Bhd (KLSE:7148) is currently trading at RM1.23 MYR, up 0.00% today. Over the past 52 weeks, shares have ranged between RM1.19 and RM1.55. This page tracks Duopharma Biotech Bhd's live share price on the KLSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Duopharma Biotech Bhd stock valuation.
Duopharma Biotech Bhd (7148) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Duopharma Biotech Bhd's daily closing share price and trading volume on the KLSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Duopharma Biotech Bhd Income Statement — Revenue, Profit & Earnings by Year
Duopharma Biotech Bhd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | RM931.69 Million | RM813.70 Million | RM704.73 Million | RM696.72 Million | RM639.17 Million |
| Cost of Revenue | RM568.55 Million | RM512.16 Million | RM436.40 Million | RM416.90 Million | RM385.19 Million |
| Gross Profit | RM363.14 Million | RM301.54 Million | RM268.33 Million | RM279.82 Million | RM253.98 Million |
| Research & Development | — | — | — | — | — |
| SG&A | RM98.18 Million | RM81.71 Million | RM82.96 Million | RM79.67 Million | RM71.13 Million |
| Total Operating Expenses | RM227.58 Million | RM200.89 Million | RM187.46 Million | RM187.40 Million | RM165.12 Million |
| Operating Income | RM135.56 Million | RM100.65 Million | RM80.87 Million | RM92.91 Million | RM88.76 Million |
| EBITDA | RM176.25 Million | RM152.01 Million | RM124.00 Million | RM130.63 Million | RM121.91 Million |
| EBIT | RM135.56 Million | RM106.62 Million | RM80.95 Million | RM94.43 Million | RM89.95 Million |
| Interest Expense | RM24.75 Million | RM26.59 Million | RM18.20 Million | RM9.10 Million | RM6.44 Million |
| Income Before Tax | RM114.91 Million | RM80.02 Million | RM63.27 Million | RM84.85 Million | RM82.98 Million |
| Income Tax Expense | RM27.45 Million | RM17.38 Million | RM10.62 Million | RM14.74 Million | RM17.30 Million |
| Net Income | RM87.46 Million | RM62.65 Million | RM52.65 Million | RM70.11 Million | RM65.68 Million |
Duopharma Biotech Bhd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Duopharma Biotech Bhd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | RM1.45 Billion | RM1.38 Billion | RM1.35 Billion | RM1.22 Billion | RM1.16 Billion |
| Total Current Assets | RM819.41 Million | RM727.05 Million | RM677.07 Million | RM541.49 Million | RM494.80 Million |
| Cash & Equivalents | — | RM128.75 Million | RM161.79 Million | RM78.54 Million | RM31.50 Million |
| Short-term Investments | — | RM32.50 Million | RM161.79 Million | RM-1.05 Million | RM-1.05 Million |
| Net Receivables | RM235.37 Million | RM207.92 Million | RM161.42 Million | RM142.15 Million | RM132.72 Million |
| Inventory | RM293.17 Million | RM248.55 Million | RM243.07 Million | RM235.18 Million | RM222.19 Million |
| Property, Plant & Equipment | — | RM567.52 Million | RM582.37 Million | RM579.92 Million | RM543.44 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | RM690.68 Million | RM667.85 Million | RM658.01 Million | RM566.70 Million | RM540.13 Million |
| Total Current Liabilities | RM313.96 Million | RM177.43 Million | RM166.73 Million | RM264.59 Million | RM230.31 Million |
| Long-term Debt | RM345.47 Million | RM464.52 Million | RM480.90 Million | RM294.60 Million | RM297.80 Million |
| Net Debt | RM202.02 Million | RM247.97 Million | RM278.35 Million | RM273.97 Million | RM265.86 Million |
| Total Stockholder Equity | RM757.62 Million | RM709.15 Million | RM687.12 Million | RM655.22 Million | RM624.00 Million |
| Retained Earnings | RM408.57 Million | RM354.78 Million | RM319.06 Million | RM288.37 Million | RM239.97 Million |
Duopharma Biotech Bhd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Duopharma Biotech Bhd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | RM112.71 Million | RM82.16 Million | RM51.55 Million | RM70.27 Million | RM43.20 Million |
| Capital Expenditures | RM26.75 Million | RM32.73 Million | RM39.56 Million | RM71.02 Million | RM115.01 Million |
| Free Cash Flow | RM85.95 Million | RM49.43 Million | RM11.99 Million | RM-756.00K | RM-71.80 Million |
| Investing Cash Flow | RM-32.99 Million | RM-26.27 Million | RM-45.98 Million | RM-69.50 Million | RM-115.86 Million |
| Financing Cash Flow | RM-54.26 Million | RM-62.42 Million | RM107.52 Million | RM18.20 Million | RM52.37 Million |
| Dividends Paid | RM33.67 Million | RM26.93 Million | RM8.85 Million | RM8.20 Million | RM44.96 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | RM40.69 Million | RM45.39 Million | RM43.05 Million | RM36.20 Million | RM31.95 Million |
| Change in Cash | RM26.33 Million | RM-5.96 Million | RM112.86 Million | RM19.66 Million | RM-20.05 Million |
Duopharma Biotech Bhd Earnings History — EPS Actual vs. Analyst Estimates
Track Duopharma Biotech Bhd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 11, 2026 | — | — | — |
| May 19, 2026 | 0.03 | — | — |
| Feb 18, 2026 | 0.02 | — | — |
| Nov 07, 2025 | 0.02 | — | — |
| Aug 13, 2025 | 0.02 | — | — |
| May 15, 2025 | 0.03 | — | — |
| Feb 20, 2025 | 0.02 | — | — |
| Nov 08, 2024 | 0.02 | — | — |